id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-340028-6oicmeam	Zhavoronkov, Alex	Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections	2020-03-31		.txt	text/plain	7228	366	36	Here we compare the expected benefit of treatments for elderly populations (60 years and older) that are currently in development, including standard preventative strategies such as vaccines and antivirals targeting SARS-CoV-2, and the potential added benefit of speculative geroprotective strategies such as rapalogs, NAD+ boosters, senolytics, and stem cell treatment. People >60 years of age with chronic medical conditions, such as type 2 diabetes or cardiovascular disease, direct immunosuppression from HIV, posttransplant or biologic treatment, pregnant individuals, or those with BMI>40, are believed to be at higher risk for influenza infection due to a weakened immune response [31] . As discussed in this paper, small clinical studies have shown that several geroprotective and senoremediative interventions, such as treatment with AGING sirolimus and rapalogs, can induce immunopotentiation, increase resistance to infection, and reduce disease severity in the elderly, without severe side effects.	./cache/cord-340028-6oicmeam.txt	./txt/cord-340028-6oicmeam.txt